Chronic Lymphocytic Leukemia (CLL) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Chronic Lymphocytic Leukemia (CLL) – Pipeline Review, H2 2016’, provides an overview of the Chronic Lymphocytic Leukemia (CLL) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Chronic Lymphocytic Leukemia (CLL), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chronic Lymphocytic Leukemia (CLL) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Chronic Lymphocytic Leukemia (CLL)

The report reviews pipeline therapeutics for Chronic Lymphocytic Leukemia (CLL) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Chronic Lymphocytic Leukemia (CLL) therapeutics and enlists all their major and minor projects

The report assesses Chronic Lymphocytic Leukemia (CLL) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Chronic Lymphocytic Leukemia (CLL)

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Chronic Lymphocytic Leukemia (CLL)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Chronic Lymphocytic Leukemia (CLL) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

4SC AG

AbbVie Inc

Acetylon Pharmaceuticals Inc

Aeglea BioTherapeutics Inc

Altor BioScience Corp

Amgen Inc

Aprea AB

Aptevo Therapeutics Inc

Arno Therapeutics Inc

ArQule Inc

Astellas Pharma Inc

Astex Pharmaceuticals Inc

Baliopharm AG

Bayer AG

BeiGene Ltd

Bellicum Pharmaceuticals Inc

Biogen Inc

Bionomics Ltd

Bionovis SA

Biothera Pharmaceutical Inc

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Company

Celgene Corp

Cellectis SA

Cellular Biomedicine Group Inc

Coherus BioSciences Inc

CrystalGenomics Inc

Cyclacel Pharmaceuticals Inc

Daiichi Sankyo Company Ltd

Eli Lilly and Company

F. Hoffmann-La Roche Ltd

GeneaMed Ltd

Genentech Inc

Genor BioPharma Co Ltd

Gilead Sciences Inc

Grupo Ferrer Internacional SA

Hutchison MediPharma Ltd

Hybrigenics SA

Igenica Biotherapeutics Inc

Immatics Biotechnologies GmbH

ImmunoGen Inc

Immunomedics Inc

Incyte Corp

Inflection Biosciences Ltd

Innate Pharma SA

Innovent Biologics Inc

Johnson & Johnson

Juno Therapeutics Inc

Kancera AB

Karyopharm Therapeutics Inc

Kite Pharma Inc

Les Laboratoires Servier SAS

LFB SA

Lymphocyte Activation Technologies SA

Medicenna Therapeutics Inc

MENTRIK Biotech LLC

Merck & Co Inc

Merck KGaA

Mesoblast Ltd

Millennium Pharmaceuticals Inc

MorphoSys AG

NantKwest Inc

Nordic Nanovector ASA

Novartis AG

Oncternal Therapeutics, Inc.

Ono Pharmaceutical Co Ltd

Panacea Biotec Ltd

PEP-Therapy SAS

Pfizer Inc

Pharmacyclics Inc

PIQUR Therapeutics AG

Portola Pharmaceuticals Inc

Redx Pharma Plc

Respiratorius AB

Revitope Oncology, Inc.

Rhizen Pharmaceuticals SA

Sandoz International GmbH

Sanofi

Selvita SA

Simcere Pharmaceutical Group

Sorrento Therapeutics Inc

Supratek Pharma Inc

Takeda Pharmaceutical Company Ltd

Targazyme Inc

TG Therapeutics Inc

The International Biotechnology Center (IBC) Generium

Theravectys SA

Tolero Pharmaceuticals Inc

TRACON Pharmaceuticals Inc

Tragara Pharmaceuticals Inc

Trillium Therapeutics Inc

United BioPharma, Inc.

Unum Therapeutics Inc

Verastem Inc

VioQuest Pharmaceuticals Inc

Viralytics Ltd

Xencor Inc

ZIOPHARM Oncology Inc

Zymeworks Inc

Table of Contents

Table of Contents

Table of Contents 2

Introduction 7

Chronic Lymphocytic Leukemia (CLL) Overview 8

Therapeutics Development 9

Chronic Lymphocytic Leukemia (CLL) - Therapeutics under Development by Companies 11

Chronic Lymphocytic Leukemia (CLL) - Therapeutics under Investigation by Universities/Institutes 20

Chronic Lymphocytic Leukemia (CLL) - Pipeline Products Glance 22

Chronic Lymphocytic Leukemia (CLL) - Products under Development by Companies 26

Chronic Lymphocytic Leukemia (CLL) - Products under Investigation by Universities/Institutes 40

Chronic Lymphocytic Leukemia (CLL) - Companies Involved in Therapeutics Development 42

Chronic Lymphocytic Leukemia (CLL) - Therapeutics Assessment 141

Drug Profiles 168

Chronic Lymphocytic Leukemia (CLL) - Dormant Projects 713

Chronic Lymphocytic Leukemia (CLL) - Discontinued Products 726

Chronic Lymphocytic Leukemia (CLL) - Product Development Milestones 728

Appendix 745

List of Tables

List of Tables

Number of Products under Development for Chronic Lymphocytic Leukemia (CLL), H2 2016 30

Number of Products under Development for Chronic Lymphocytic Leukemia (CLL) – Comparative Analysis, H2 2016 31

Number of Products under Development by Companies, H2 2016 33

Number of Products under Development by Companies, H2 2016 (Contd..1) 34

Number of Products under Development by Companies, H2 2016 (Contd..2) 35

Number of Products under Development by Companies, H2 2016 (Contd..3) 36

Number of Products under Development by Companies, H2 2016 (Contd..4) 37

Number of Products under Development by Companies, H2 2016 (Contd..5) 38

Number of Products under Development by Companies, H2 2016 (Contd..6) 39

Number of Products under Development by Companies, H2 2016 (Contd..7) 40

Number of Products under Investigation by Universities/Institutes, H2 2016 42

Comparative Analysis by Late Stage Development, H2 2016 43

Comparative Analysis by Clinical Stage Development, H2 2016 44

Comparative Analysis by Early Stage Development, H2 2016 45

Comparative Analysis by Unknown Stage Development, H2 2016 46

Products under Development by Companies, H2 2016 47

Products under Development by Companies, H2 2016 (Contd..1) 48

Products under Development by Companies, H2 2016 (Contd..2) 49

Products under Development by Companies, H2 2016 (Contd..3) 50

Products under Development by Companies, H2 2016 (Contd..4) 51

Products under Development by Companies, H2 2016 (Contd..5) 52

Products under Development by Companies, H2 2016 (Contd..6) 53

Products under Development by Companies, H2 2016 (Contd..7) 54

Products under Development by Companies, H2 2016 (Contd..8) 55

Products under Development by Companies, H2 2016 (Contd..9) 56

Products under Development by Companies, H2 2016 (Contd..10) 57

Products under Development by Companies, H2 2016 (Contd..11) 58

Products under Development by Companies, H2 2016 (Contd..12) 59

Products under Development by Companies, H2 2016 (Contd..13) 60

Products under Investigation by Universities/Institutes, H2 2016 61

Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 62

Chronic Lymphocytic Leukemia (CLL) – Pipeline by 4SC AG, H2 2016 63

Chronic Lymphocytic Leukemia (CLL) – Pipeline by AbbVie Inc, H2 2016 64

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Acetylon Pharmaceuticals Inc, H2 2016 65

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Aeglea BioTherapeutics Inc, H2 2016 66

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Altor BioScience Corp, H2 2016 67

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Amgen Inc, H2 2016 68

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Aprea AB, H2 2016 69

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Aptevo Therapeutics Inc, H2 2016 70

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Arno Therapeutics Inc, H2 2016 71

Chronic Lymphocytic Leukemia (CLL) – Pipeline by ArQule Inc, H2 2016 72

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Astellas Pharma Inc, H2 2016 73

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Astex Pharmaceuticals Inc, H2 2016 74

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Baliopharm AG, H2 2016 75

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Bayer AG, H2 2016 76

Chronic Lymphocytic Leukemia (CLL) – Pipeline by BeiGene Ltd, H2 2016 77

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Bellicum Pharmaceuticals Inc, H2 2016 78

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Biogen Inc, H2 2016 79

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Bionomics Ltd, H2 2016 80

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Bionovis SA, H2 2016 81

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Biothera Pharmaceutical Inc, H2 2016 82

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Boehringer Ingelheim GmbH, H2 2016 83

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Bristol-Myers Squibb Company, H2 2016 84

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Celgene Corp, H2 2016 85

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Cellectis SA, H2 2016 86

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Cellular Biomedicine Group Inc, H2 2016 87

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Coherus BioSciences Inc, H2 2016 88

Chronic Lymphocytic Leukemia (CLL) – Pipeline by CrystalGenomics Inc, H2 2016 89

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Cyclacel Pharmaceuticals Inc, H2 2016 90

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Daiichi Sankyo Company Ltd, H2 2016 91

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Eli Lilly and Company, H2 2016 92

Chronic Lymphocytic Leukemia (CLL) – Pipeline by F. Hoffmann-La Roche Ltd, H2 2016 93

Chronic Lymphocytic Leukemia (CLL) – Pipeline by GeneaMed Ltd, H2 2016 94

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Genentech Inc, H2 2016 95

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Genor BioPharma Co Ltd, H2 2016 96

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Gilead Sciences Inc, H2 2016 97

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Grupo Ferrer Internacional SA, H2 2016 98

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Hutchison MediPharma Ltd, H2 2016 99

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Hybrigenics SA, H2 2016 100

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Igenica Biotherapeutics Inc, H2 2016 101

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Immatics Biotechnologies GmbH, H2 2016 102

Chronic Lymphocytic Leukemia (CLL) – Pipeline by ImmunoGen Inc, H2 2016 103

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Immunomedics Inc, H2 2016 104

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Incyte Corp, H2 2016 105

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Inflection Biosciences Ltd, H2 2016 106

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Innate Pharma SA, H2 2016 107

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Innovent Biologics Inc, H2 2016 108

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Johnson & Johnson, H2 2016 109

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Juno Therapeutics Inc, H2 2016 110

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Kancera AB, H2 2016 111

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Karyopharm Therapeutics Inc, H2 2016 112

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Kite Pharma Inc, H2 2016 113

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Les Laboratoires Servier SAS, H2 2016 114

Chronic Lymphocytic Leukemia (CLL) – Pipeline by LFB SA, H2 2016 115

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Lymphocyte Activation Technologies SA, H2 2016 116

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Medicenna Therapeutics Inc, H2 2016 117

Chronic Lymphocytic Leukemia (CLL) – Pipeline by MENTRIK Biotech LLC, H2 2016 118

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Merck & Co Inc, H2 2016 119

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Merck KGaA, H2 2016 120

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Mesoblast Ltd, H2 2016 121

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Millennium Pharmaceuticals Inc, H2 2016 122

Chronic Lymphocytic Leukemia (CLL) – Pipeline by MorphoSys AG, H2 2016 123

Chronic Lymphocytic Leukemia (CLL) – Pipeline by NantKwest Inc, H2 2016 124

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Nordic Nanovector ASA, H2 2016 125

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Novartis AG, H2 2016 126

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Oncternal Therapeutics, Inc., H2 2016 127

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Ono Pharmaceutical Co Ltd, H2 2016 128

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Panacea Biotec Ltd, H2 2016 129

Chronic Lymphocytic Leukemia (CLL) – Pipeline by PEP-Therapy SAS, H2 2016 130

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Pfizer Inc, H2 2016 131

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Pharmacyclics Inc, H2 2016 132

Chronic Lymphocytic Leukemia (CLL) – Pipeline by PIQUR Therapeutics AG, H2 2016 133

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Portola Pharmaceuticals Inc, H2 2016 134

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Redx Pharma Plc, H2 2016 135

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Respiratorius AB, H2 2016 136

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Revitope Oncology, Inc., H2 2016 137

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Rhizen Pharmaceuticals SA, H2 2016 138

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Sandoz International GmbH, H2 2016 139

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Sanofi, H2 2016 140

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Selvita SA, H2 2016 141

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Simcere Pharmaceutical Group, H2 2016 142

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Sorrento Therapeutics Inc, H2 2016 143

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Supratek Pharma Inc, H2 2016 144

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Takeda Pharmaceutical Company Ltd, H2 2016 145

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Targazyme Inc, H2 2016 146

Chronic Lymphocytic Leukemia (CLL) – Pipeline by TG Therapeutics Inc, H2 2016 147

Chronic Lymphocytic Leukemia (CLL) – Pipeline by The International Biotechnology Center (IBC) Generium, H2 2016 148

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Theravectys SA, H2 2016 149

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Tolero Pharmaceuticals Inc, H2 2016 150

Chronic Lymphocytic Leukemia (CLL) – Pipeline by TRACON Pharmaceuticals Inc, H2 2016 151

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Tragara Pharmaceuticals Inc, H2 2016 152

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Trillium Therapeutics Inc, H2 2016 153

Chronic Lymphocytic Leukemia (CLL) – Pipeline by United BioPharma, Inc., H2 2016 154

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Unum Therapeutics Inc, H2 2016 155

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Verastem Inc, H2 2016 156

Chronic Lymphocytic Leukemia (CLL) – Pipeline by VioQuest Pharmaceuticals Inc, H2 2016 157

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Viralytics Ltd, H2 2016 158

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Xencor Inc, H2 2016 159

Chronic Lymphocytic Leukemia (CLL) – Pipeline by ZIOPHARM Oncology Inc, H2 2016 160

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Zymeworks Inc, H2 2016 161

Assessment by Monotherapy Products, H2 2016 162

Assessment by Combination Products, H2 2016 163

Number of Products by Stage and Target, H2 2016 165

Number of Products by Stage and Mechanism of Action, H2 2016 175

Number of Products by Stage and Route of Administration, H2 2016 186

Number of Products by Stage and Molecule Type, H2 2016 188

Chronic Lymphocytic Leukemia (CLL) – Dormant Projects, H2 2016 734

Chronic Lymphocytic Leukemia (CLL) – Dormant Projects (Contd..1), H2 2016 735

Chronic Lymphocytic Leukemia (CLL) – Dormant Projects (Contd..2), H2 2016 736

Chronic Lymphocytic Leukemia (CLL) – Dormant Projects (Contd..3), H2 2016 737

Chronic Lymphocytic Leukemia (CLL) – Dormant Projects (Contd..4), H2 2016 738

Chronic Lymphocytic Leukemia (CLL) – Dormant Projects (Contd..5), H2 2016 739

Chronic Lymphocytic Leukemia (CLL) – Dormant Projects (Contd..6), H2 2016 740

Chronic Lymphocytic Leukemia (CLL) – Dormant Projects (Contd..7), H2 2016 741

Chronic Lymphocytic Leukemia (CLL) – Dormant Projects (Contd..8), H2 2016 742

Chronic Lymphocytic Leukemia (CLL) – Dormant Projects (Contd..9), H2 2016 743

Chronic Lymphocytic Leukemia (CLL) – Dormant Projects (Contd..10), H2 2016 744

Chronic Lymphocytic Leukemia (CLL) – Dormant Projects (Contd..11), H2 2016 745

Chronic Lymphocytic Leukemia (CLL) – Dormant Projects (Contd..12), H2 2016 746

Chronic Lymphocytic Leukemia (CLL) – Discontinued Products, H2 2016 747

Chronic Lymphocytic Leukemia (CLL) – Discontinued Products (Contd..1), H2 2016 748

List of Figures

List of Figures

Number of Products under Development for Chronic Lymphocytic Leukemia (CLL), H2 2016 30

Number of Products under Development for Chronic Lymphocytic Leukemia (CLL) – Comparative Analysis, H2 2016 31

Number of Products under Development by Companies, H2 2016 32

Number of Products under Investigation by Universities/Institutes, H2 2016 41

Comparative Analysis by Late Stage Development, H2 2016 43

Comparative Analysis by Clinical Stage Development, H2 2016 44

Comparative Analysis by Early Stage Products, H2 2016 45

Assessment by Monotherapy Products, H2 2016 162

Assessment by Combination Products, H2 2016 163

Number of Products by Top 10 Targets, H2 2016 164

Number of Products by Stage and Top 10 Targets, H2 2016 164

Number of Products by Top 10 Mechanism of Actions, H2 2016 174

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 174

Number of Products by Routes of Administration, H2 2016 185

Number of Products by Stage and Routes of Administration, H2 2016 185

Number of Products by Top 10 Molecule Types, H2 2016 187

Number of Products by Stage and Top 10 Molecule Types, H2 2016 187

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports